Benserazide-d3 (hydrochloride)

Benserazide-d3 (hydrochloride)

• UNSPSC Description: Benserazide-d3 (hydrochloride) is the deuterium labeled Benserazide hydrochloride. Benserazide hydrochloride (Serazide) is commonly used in Parkinson's disease and is an inhibitor of peripheral aromatic L-amino acid decarboxylase (AADC)[1].
• Target Antigen: Isotope-Labeled Compounds
• Type: Isotope-Labeled Compounds
• Related Pathways: Others
• Field of Research: Neurological Disease
• Solubility: 10 mM in DMSO
• Smiles: O=C(C(C([2H])([2H])O)([2H])N)NNCC1=CC=C(C(O)=C1O)O.Cl
• Molecular Weight: 296.72
• References & Citations: [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. |[2]Shen H, et al. Effects of benserazide on L-DOPA-derived extracellular dopamine levels and aromatic L-amino acid decarboxylase activity in the striatum of 6-hydroxydopamine-lesioned rats. Tohoku J Exp Med. 2003 Mar;199(3):149-59.|[3]Chandel TI, et al. A multiparametric analysis of the synergistic impact of anti-Parkinson's drugs on the fibrillation of human serum albumin. Biochim Biophys Acta Proteins Proteom. 2019 Mar;1867(3):275-285.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported